CNTA Centessa Pharmaceuticals plc
USHealthcareAs of 2026-06-25 16:00
Why CNTA matters now
Centessa Pharmaceuticals plc (CNTA) is a US stock in Healthcare. The latest InvestLog snapshot shows $40.50 with +0.00% on the session and $6.27B in market capitalization; recent performance reads 1-month +0.81% and YTD +60.02%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-79.2M, and EPS of $-0.52. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -3.4%.
The latest indexable market news headline is "Acquisition of Centessa by Lilly Approved by the High Court of Justice of England and Wales" from GlobeNewsWire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $39.00; recent insider activity includes Accardi Mario Alberto filing F-InKind. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
12.61
P/S
0.00
EV/EBITDA
-23.55
DCF Value
$1.12
FCF Yield
-3.4%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-60.4%
ROA
-39.1%
ROIC
-42.4%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-79.2M | $-0.52 |
| Q4 2025 | $0.00 | $-66.2M | $-0.47 |
| FY 2025 | $15.0M | $-197.5M | $-1.46 |
| Q3 2025 | $0.00 | $-54.9M | $-0.41 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$39.50
Target (Median)
$39.00
Target Range
$38.00 - $42.00
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Biotechnology
Country
GB
Exchange
—
Beta
1.12
Centessa Pharmaceuticals plc operates as a clinical-stage pharmaceutical enterprise focused on discovering, developing, and ultimately providing therapeutic solutions to patients. The company's most advanced product candidates include Lixivaptan, a small molecule inhibitor of the vasopressin V2 receptor, which is currently undergoing Phase III clinical evaluation for treating autosomal dominant polycystic kidney disease. Additionally, SerpinPC, an activated protein C inhibitor, is progressing through Phase IIa clinical development for the management of hemophilia A and B. Centessa's pipeline also features several emerging assets in the clinical proof-of-concept stage. These comprise LB101 (a PD-L1xCD47 LockBody) and LB201 (a PD-L1xCD3 LockBody), both engineered to selectively activate potent CD47 and CD3 effector functions while minimizing systemic side effects. Another molecule, ZF874, is a small molecule pharmacological chaperone in Phase I studies, designed to correct the misfolding of the Z variant of alpha-1-antitrypsin, thus addressing alpha-1-antitrypsin deficiency. Furthermore, MGX292, a recombinant modified BMP9 replacement protein, aims to rectify the deficient BMP9 signaling implicated in Pulmonary Arterial Hypertension. The company is also developing OX2R Agonists, which are selective orexin receptor 2 agonists (available as oral and intranasal formulations) intended to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1 by leveraging structural insights. Beyond these, Centessa is exploring further clinical proof-of-concept compounds. CBS001, an anti-LIGHT antibody, is being investigated for inflammatory and fibrotic diseases due to its preferential binding to the inflammatory membrane form of LIGHT. Lastly, CBS004 is a humanized monoclonal antibody specifically targeting BDCA2, a protein found exclusively on plasmacytoid dendritic cells, with potential utility in conditions such as systemic sclerosis, systemic lupus erythematosus, and other autoimmune disorders. Centessa Pharmaceuticals plc was established in 2020 and is headquartered in Altrincham, United Kingdom.